Medicines: Acalabrutinib

Evaluating acalabrutinib in CLL treatment

VJHemOnc – Video Journal of Hematology & HemOnc

Acalabrutinib Versus Ibrutinib for CLL

Targeted Oncology

How CALQUENCE® (acalabrutinib) Works

CALQUENCE (acalabrutinib)

The current role of acalabrutinib in the treatment of CLL

VJHemOnc – Video Journal of Hematology & HemOnc

CALQUENCE® (acalabrutinib) Perspectives: Dr Alexey Danilov, MD, PhD

CALQUENCE (acalabrutinib)

BTK inhibitors for CLL: acalabrutinib vs ibrutinib

VJHemOnc – Video Journal of Hematology & HemOnc

Acalabrutinib’s Role in Treating Chronic Lymphocytic Leukemia

CALQUENCE® (acalabrutinib) ACE-CL-001 (ibrutinib-intolerant cohort) – Dr Raval, MD

CALQUENCE (acalabrutinib)

Acalabrutinib Shows Promising Results for the Treatment of CLL

Targeted Oncology

CALQUENCE® (acalabrutinib) Mechanism of Action (MOA) – Dr Pearson, MD

CALQUENCE (acalabrutinib)

CALQUENCE® (acalabrutinib) Clinical Insights from a Real-World Patient with Treatment Naive CLL

CALQUENCE (acalabrutinib)

Acalabrutinib And Zanubrutinib in CLL

Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCL

Acalabrutinib for the treatment of Richter's transformation and patients with ibrutinib intolerance

VJHemOnc – Video Journal of Hematology & HemOnc

Acalabrutinib and AZD9150 combination for the treatment of R/R DLBCL

VJHemOnc – Video Journal of Hematology & HemOnc

EPIC update: observational study of first-line acalabrutinib treatment for CLL

VJHemOnc – Video Journal of Hematology & HemOnc

Acalabrutinib and rituximab as first-line therapy for older patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Acalabrutinib, Second-Generation BTK Inhibitor for CLL

Acalabrutinib Treatment Considerations in CLL

Targeted Oncology

Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL

VJHemOnc – Video Journal of Hematology & HemOnc